YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer, Chairman, and Founder - Hermann Luebbert Chief Commercial Officer - George Jones Chief Financial Officer - Fred Leffler Fu…
Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer, Chairman, and Founder — Hermann Lubbert Chief Commercial Officer — George Jones Chief Financial Officer — Eugene Leffler…
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will partici…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to Buy…
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items. Th…
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it…
Biofrontera Inc. Q4 2025 Earnings Call Summary - Moby Strategic Pivot and Commercial Execution Achieved record annual revenue of $41.7 million, driven by a 10% increase in Ameluz unit volumes and refined commercial targeting. Transformed t…
Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer, Chairman, and Founder — Hermann Lubbert Chief Commercial Officer — George Jones Chief Financial Officer — Fred Leffler Ne…
Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 10 a.m. ET CALL PARTICIPANTS Chief Executive Officer, Chairman, and Founder — Hermann LubbertChief Commercial Officer — George JonesChief Financial Officer — Fred Leffler Need…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Align Technology (ALGN) been one of those stocks this year? By taking a look at the stock's year-to…
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces…
(RTTNews) - Biofrontera Inc. (BFRI), Monday announced positive and statistically significant top-line results from its Phase 3 clinical trial, evaluating Ameluz PDT with the red-light LEDplatform for the treatment of mild to moderate actin…
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission…
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met…
Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commerci…
* Biofrontera press release [https://seekingalpha.com/filing/38897076] (BFRI [https://seekingalpha.com/symbol/BFRI]): Q3 GAAP EPS of -$0.62. * Revenue of $6.98M (-22.5% Y/Y). MORE ON BIOFRONTERA * Seeking Alpha’s Quant Rating on Biofronter…
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring item…
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expe…
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ…
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago. These figures are adjusted for non-recurrin…
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of a loss of $1.19 per share. This compares to a loss of $1.39 per share a year ago. These figures are adjusted for non-recurr…
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–…
Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will par…
WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engage…
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supp…
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in…
Earnings Call Insights: Biofrontera Inc. (BFRI) Q2 2025 MANAGEMENT VIEW * CEO Hermann Luebbert highlighted a "record breaking" performance in the first half of 2025, driven by a shift in customer segmentation strategy, data-driven sales su…
Biofrontera Inc. (BFRI) reported its financial results for the second quarter of 2025, highlighting a 15.4% increase in total revenues compared to the same period last year. Despite the revenue growth, the company posted a net loss of $5.3…
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financia…
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of G…
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-rec…
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurri…
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financia…
* Biofrontera (NASDAQ:BFRI [https://seekingalpha.com/symbol/BFRI]) filed a prospectus to sale 13.6 million shares of class A common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling sharehol…
Biofrontera (NASDAQ:BFRI [https://seekingalpha.com/symbol/BFRI]) said on Monday that it has acquired [https://seekingalpha.com/pr/20151642-biofrontera-inc-announces-major-restructuring-of-relationship-with-biofrontera-ag-backed-by]all U.S.…
WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of…